SENORES PHARMACEUTICALS L (SENORES) - Cash Flow Conversion Efficiency
Based on the latest financial reports, SENORES PHARMACEUTICALS L (SENORES) has a cash flow conversion efficiency ratio of 0.029x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs242.20 Million ≈ $2.62 Million USD) by net assets (Rs8.34 Billion ≈ $90.24 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how many days can SENORES PHARMACEUTICALS L fund operations to measure how many days the company can operate on defensive assets alone.
SENORES PHARMACEUTICALS L - Cash Flow Conversion Efficiency Trend (2022–2025)
This chart illustrates how SENORES PHARMACEUTICALS L's cash flow conversion efficiency has evolved over time, based on yearly financial data.
SENORES PHARMACEUTICALS L Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of SENORES PHARMACEUTICALS L ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
EirGenix
TWO:6589
|
-0.020x |
|
DukSan Neolux Co.Ltd
KQ:213420
|
0.043x |
|
Hyundai Home Shopping Network Corp
KO:057050
|
0.002x |
|
Terrestrial Energy Inc
NASDAQ:IMSR
|
-0.052x |
|
APG SGA SA
SW:APGN
|
0.000x |
|
Wuhan Sanzhen Industry Holding Co Ltd
SHG:600168
|
0.023x |
|
China Oil HBP Science & Technology Co Ltd
SHE:002554
|
-0.120x |
|
Sejin Heavy Industries Co Ltd
KO:075580
|
0.100x |
Annual Cash Flow Conversion Efficiency for SENORES PHARMACEUTICALS L (2022–2025)
The table below shows the annual cash flow conversion efficiency of SENORES PHARMACEUTICALS L from 2022 to 2025. For the full company profile with market capitalisation and key ratios, see SENORES company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | Rs94.96 Million ≈ $1.03 Million |
Rs-459.20 Million ≈ $-4.97 Million |
-4.836x | -4260.01% |
| 2024-03-31 | Rs2.32 Billion ≈ $25.06 Million |
Rs-257.00 Million ≈ $-2.78 Million |
-0.111x | -367.70% |
| 2023-03-31 | Rs454.99 Million ≈ $4.92 Million |
Rs-10.79 Million ≈ $-116.69K |
-0.024x | +91.69% |
| 2022-03-31 | Rs365.90 Million ≈ $3.96 Million |
Rs-104.47 Million ≈ $-1.13 Million |
-0.286x | -- |
About SENORES PHARMACEUTICALS L
Senores Pharmaceuticals Limited develops, manufactures, sells, and trades in pharmaceutical and allied products in India, the United States, the United Kingdom, Canada, and internationally. It offers pharmaceutical solutions, such as analgesic/antipyretic, anesthetics and allied products, antibacterial/antibiotic, antiviral, antifungal, antioxidants, antineoplastic, blood line, cardiovascular, ne… Read more